Effect of extended-release niacin on cardiovascular events and kidney function in XXXX : a post hoc analysis of the AIM-HIGH trial.

@entity1 @entity301 @entity470 @entity740 @entity65
@entity740 ( @entity740 ) in @entity1 is strongly associated with @entity65 and mortality, and prevalent abnormal lipid metabolism. The AIM-HIGH trial examined the benefits of adding extended-release niacin (ERN) to simvastatin in @entity1 with established @entity301 . Here we conducted a post hoc analysis of the AIM-HIGH trial examining whether @entity1 derived cardiovascular or renal benefits when stratified by renal function. Of 3414 @entity1 , 505 had stage 3 @entity740 at baseline. Among the @entity740 subset, demographics and @entity65 ( @entity65 ) risk factors were well balanced in the ERN and placebo arms. Compared with placebo, @entity740 @entity1 receiving ERN had a significant decrease in triglycerides by a median of 59.0   mg/dl, and high-density lipoprotein cholesterol significantly increased by a mean of 11.3   mg/dl over a mean follow-up of 3 years. @entity65 events were similar between @entity740 @entity1 in both arms. However, all-cause mortality was significantly higher in the ERN group (hazard ratio of 1.73). Mean change in @entity470 among ERN-treated @entity740 @entity1 was not significantly different between study arms. Thus, among AIM-HIGH @entity1 with @entity740 , the addition of ERN to simvastatin for secondary prevention of @entity65 improved triglyceride and high-density lipoprotein-cholesterol concentrations but did not improve cardiovascular outcomes or kidney function, and was associated with higher all-cause mortality.
